Trial Profile
A Study to Evaluate the Efficacy of Gefitinib in Elderly Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Dec 2015
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 09 Dec 2015 New trial record